Spots Global Cancer Trial Database for Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Official Title: A Phase II Study of IL-6 Receptor Blockade to Ameliorate Acute Graft Versus Host Disease and Early Toxicity After Double Unit Cord Blood Transplantation in Adults With Hematologic Malignancies.

Study ID: NCT03434730

Conditions

Acute Myeloid Leukemia

Acute Lymphoblastic Leukemia

Acute Leukemia

Myelodysplastic Syndromes

Myelodysplastic-Myeloproliferative Diseases

Myeloproliferative Disorder

Non Hodgkin Lymphoma

Hodgkin Lymphoma

Leukemia

Interventions

Total Body Irradiation

Cyclosporine

Mycophenolate Mofetil

Tocilizumab

Filgrastim

Study Description

Brief Summary: The aim of the research in this study is to make participants' transplant safer by reducing the risk of developing GVHD and GVHD-related complications by giving participants a dose of the drug tocilizumab in addition to the standard approach for GVHD prevention. Tocilizumab reduces the risk of inflammation by blocking the effect of Interleukin-6, a protein that exists in high levels in the blood when there is inflammation. Participants who receive stem cell transplants have high levels of this protein in their blood early after transplant. Therefore, the goal of this study is to reduce the risk of inflammation after transplant with the addition of Tocilizumab. This could decrease the risk of developing GVHD and GVHD-associated complications.

Detailed Description: